Insulin Analogs for Type 1 Diabetes Management

Abstract

Type 1 diabetes is a metabolic dysfunction in which there is the autoimmune destruction of the β cells in the islet of Langerhans; thereby, there is very little or no insulin production.1 Insulin regulates the blood glucose level in the body, and there is no known way of preventing type 1 diabetes.35 Blood glucose homeostasis is vital to avoid further complications, and hence they need insulin analogs to mimic the same. Regular insulin has limitations on how it mimics the bolus insulin secretion. By changing the amino acid sequence in the DNA through genetic engineering, insulin analogs can have different characteristics from natural insulin, which helps overcome these shortcomings. Rapid-acting, long-acting, and mixed formulations are subcategories of insulin analogs. These can help mimic the pattern of insulin release in a healthy individual. Intravenous and subcutaneous administrations influence how fast the insulin analogs can act. The success of each analog depends on how close its action is to natural insulin. All-analog basal bonus regimens show lower glycosylated hemoglobin than all-human insulin basal bonus regimens. Generally, analogs do not have adverse side effects. Therefore, analogs have a significant role in preventing type 1 diabetes from developing into a potentially fatal disease.9 This article even projects the prospects of insulin analogs like inhalers and oral administrations.